Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.88
+3.6%
$19.96
$11.45
▼
$22.13
$7.36B1.243.85 million shs2.01 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$156.23
-0.9%
$159.02
$105.88
▼
$200.00
$6.35B-1.19170,573 shs94,252 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$1.71
+0.6%
$4.36
$1.55
▼
$35.29
$14.62M1.47133,211 shs96,145 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-0.52%-1.22%+10.11%+16.62%+82.38%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-2.98%+0.77%+10.46%-6.43%+34.91%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-6.08%-9.57%-65.73%-66.80%-94.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$21.88
+3.6%
$19.96
$11.45
▼
$22.13
$7.36B1.243.85 million shs2.01 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$156.23
-0.9%
$159.02
$105.88
▼
$200.00
$6.35B-1.19170,573 shs94,252 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$1.71
+0.6%
$4.36
$1.55
▼
$35.29
$14.62M1.47133,211 shs96,145 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-0.52%-1.22%+10.11%+16.62%+82.38%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-2.98%+0.77%+10.46%-6.43%+34.91%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-6.08%-9.57%-65.73%-66.80%-94.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
2.80
Moderate Buy$23.005.12% Upside
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.67
Moderate Buy$226.9145.24% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
1.67
Reduce$47.002,648.54% Upside

Current Analyst Ratings Breakdown

Latest AMRX, SNWV, and BLTE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Boost Price TargetOutperform$221.00 ➝ $230.00
11/16/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Boost Price TargetBuy$303.00 ➝ $314.00
11/13/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Boost Price TargetOutperform$185.00 ➝ $215.00
11/10/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
DowngradeBuy (B) ➝ Hold (C+)
11/5/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOutperform$23.00 ➝ $25.00
11/4/2026
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
UpgradeSell (D) ➝ Sell (D+)
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Reiterated RatingOverweight$21.00
11/4/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Boost Price TargetOverweight$24.00 ➝ $25.00
10/29/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Reiterated RatingBuy$24.00
10/26/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
UpgradeStrong Sell ➝ Hold
10/23/2026
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
DowngradeSell (D+) ➝ Sell (D)
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$3.02B2.53$1.62 per share13.52$1.52 per share14.39
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$19.15 per shareN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$44.05M0.33$1.71 per share1.00$0.33 per share5.18
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$72.06M$0.4222.2319.362.404.17%283.50%7.79%N/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.73N/A214.01N/AN/A-9.95%-9.76%N/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$11.81M-$0.38N/AN/AN/A6.22%113.13%7.17%N/A

Latest AMRX, SNWV, and BLTE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.7863-$0.60+$0.1863-$0.75N/AN/A
11/10/2026Q3 2026
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$0.01-$0.16-$0.17-$0.16$13.75 million$8.58 million
11/3/2026Q3 2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$0.23$0.26+$0.03-$0.06N/A$862.68 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
5.61
1.87
1.24
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
26.68
26.68
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
4.01
1.18
0.77

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
17.30%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,500348.41 million288.14 millionOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
4140.27 million34.92 millionOptionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
558.60 million7.36 millionN/A

Recent News About These Companies

Sanuwave Q3 Revenue Falls 24% to $8.6 Million
Sanuwave Announces Q3 FY2026 Financial Results
SANUWAVE Health, Inc. Common Stock (SNWV) Earnings
SANUWAVE Health Inc.
Sanuwave Announces Q2 FY2026 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$21.88 +0.76 (+3.60%)
Closing price 04:00 PM Eastern
Extended Trading
$21.63 -0.25 (-1.16%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$156.23 -1.49 (-0.94%)
Closing price 04:00 PM Eastern
Extended Trading
$156.73 +0.50 (+0.32%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$1.71 +0.01 (+0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.68 -0.03 (-1.70%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.